(Total Views: 546)
Posted On: 05/13/2025 3:35:36 PM
Post# of 154756
Riz: Great find (with credit to Upwithstock). I had earlier mentioned that GSK also has a ICI (Jemperli), but now I'm more focused on Roche, which has a PDL-1 inhibitor, Atezolizumab. Recall that the abstract for the poster indicated that 4 of the 5 LL survivors also received Atrzolizumab (the 5th received Keytruda). And, of course, the PR makes the point that the MOA seems to thrive when LL is combined with an ICI.
Roche is also a trigger for me because it is a Swiss company, and I have repeatedly speculated that treks by cash poor CYDY to major oncology conferences in Munich, Barcelona, and Vienna within a 2 month window scream a particular focus on the licensing jurisdiction of the EMA, where Roche is a major player.
I'm still knee deep in I don't know what I don't know, but:
Stay tuned.
Roche is also a trigger for me because it is a Swiss company, and I have repeatedly speculated that treks by cash poor CYDY to major oncology conferences in Munich, Barcelona, and Vienna within a 2 month window scream a particular focus on the licensing jurisdiction of the EMA, where Roche is a major player.
I'm still knee deep in I don't know what I don't know, but:
Stay tuned.
(21)
(0)
